@article{524997ecb20d4849af245e1e571de6e1,
title = "Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study)",
abstract = "This report focuses on the subset of 235 patients from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study receiving randomly assigned medical therapy to treat angina and suppress ischemia detected on ambulatory electrocardiography: 121 patients received the sequence of atenolol and nifedipine, and 114 diltiazem and isosorbide dinitrate. After 12 weeks of therapy, the primary end Point (absence of ambulatory electrocardiographic (ECG) ischemia and no clinical events) was reached in 47% of atenolol/nifedipine- versus 31% of diltiazem/isosorbide dinitrate-treated patients (adjusted p=0.03). A trend to increased exercise time to ST depression was seen in the atenolol and nifedipine versus diltiazem and isosorbide dinitrate regimens (median treadmill duration 5.8 vs 4.8 minutes; p=0.04). However, when adjusted for baseline imbalances in ambulatory ECG ischemia, the 2 medical combinations were similar in suppression of ambulatory ECG ischemia. In both medication regimens, an association between mean heart rate and ischemia on ambulatory electrocardiography after 12 weeks of treatment was observed so that patients on either regimen with a mean heart rate >80 beats/min had ischemia detectable almost twice as often as those with a mean heart rate <70 beats/min (p <0.001).",
author = "Pratt, {Craig M.} and McMahon, {Robert P.} and Sidney Goldstein and Pepine, {Carl J.} and Andrews, {Thomas C.} and Ihor Dyrda and Frishman, {William H.} and Geller, {Nancy L.} and Hill, {James A.} and Morgan, {Nancy A.} and Stone, {Peter H.} and Knatterud, {Genell L.} and George Sopko and Conti, {C. Richard}",
note = "Funding Information: From the Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas. This work was presented, in part, at the Scientific Session of the American Heart Association in Dallas, Texas, in November 1994. This study was funded by Research Contracts HV-90-07, HV-9048, and HV-91-05 to HV-91-14 from the National Heart, lung, and Blood Institute, Cardiac Diseases Branch, Division of Heart and Vascular Disease. National Institutes of Health Bethesda, Maryland. Stud medications and placebo were donated by Zeneca Pharmaceutics Ys Group, Wilmington, Delaware; Marion-Merrell Dow, Kansas City, Missouri; and Pfizer, New York, New York. Support for electrocardiographic data collection was provided in part by Applied Cardiac Systems, laguna Hills, California; Marquette Electronics, Milwaukee, Wisconsin; Mortara Instrument, Milwaukee, Wisconsin; and Qutnton Instruments, Seattle, Washington. Some centers had partial support from General Clinical Research Center grants. A complete list of the ACIP investigators and centers participating in the ACIP study was published previously in.JAm Co// Cardiol 1995;26:594-605. M anuscript received September 25, 1995; revised manuscript received and accepted February 1, 1996. Address for reprints: Genell Knatterud, PhD, ACIP Clinical Coordinating Center, Maryland Medical Research Institute, 600 Wynd-burst Avenue, Baltimore, Maryland 2 12 10.",
year = "1996",
month = jun,
day = "15",
doi = "10.1016/S0002-9149(96)00196-8",
language = "English (US)",
volume = "77",
pages = "1302--1309",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "15",
}